Novo Nordisk A/S Sponsored ADR (NVO)
Mizuho's Jared Holz: Novo Nordisk is trying to come up with strategies to regain market share
Jared Holz, Mizuho Securities health care strategist, joins CNBC's 'Squawk on the Street' to discuss weight loss drug makers, how CVS is boosting access to Wegovy, and more.
Insight: How Novo Nordisk misread the US market for its weight loss sensation
Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, leaving the Danish drugmaker in a more vulnerable position when rival Eli Lilly entered the market, six former employees involved in the discussions told Reuters.
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking
With the notable exceptions of Novo Nordisk A/S NYSE: NVO and Eli Lilly & Co. NYSE: LLY, biotechnology stocks had a rough time attracting investment capital in 2024. Small- and mid-cap biotech stocks struggled to raise capital in a higher-for-longer interest rate environment.
NVO vs. LLY: Which Obesity Powerhouse is the Stronger Bet Now?
Eli Lilly edges ahead of Novo Nordisk as the stronger obesity bet, backed by robust sales growth, pipeline depth and strategic momentum.
Novo Nordisk to Expand Access to Wegovy with WeightWatchers Partnership
The pharmaceutical giant said WeightWatchers will work with CenterWell Pharmacy to fulfill and deliver Wegovy prescriptions.
CHMP Backs NVO's Ozempic EU Label Update for Cardiovascular Indication
CHMP recommends a label update for Novo Nordisk's Ozempic after the STRIDE study shows walking improvements in T2D patients with PAD.
EU drug regulator allows Novo Nordisk to include heart condition in Ozempic label
Novo Nordisk said on Monday the European drugs regulator has adopted a positive opinion for an update of the Ozempic label to include peripheral artery disease.
NVO Reports New Positive Phase III Data on Mim8 in Hemophilia A
Novo Nordisk's Mim8 shows strong safety and patient preference in the phase IIIb hemophilia A study switching from Hemlibra to Mim8.
Hims & Hers shares drop after Novo Nordisk ends Wegovy collaboration over compounding practices
Shares of Hims & Hers Health (NYSE:HIMS) fell around 30% on Monday after Novo Nordisk (NYSE:NVO) terminated its collaboration with the telehealth company, citing violations related to compounding and marketing of the weight-loss drug Wegovy. Novo said it ended Hims & Hers' access to the FDA-approved treatment through its NovoCare platform, alleging that the company engaged in illegal mass compounding and deceptive marketing.
Hims & Hers stock crashes over 20% on Wegovy shocker
Hims & Hers Health (NYSE: HIMS) stock has plunged sharply after Novo Nordisk (NYSE: NVO) announced it was severing ties with the telehealth firm over concerns about the distribution of its weight loss drug, Wegovy.
Novo Nordisk's new obesity drug hits high efficacy marks, but investors stay cautious
Novo Nordisk (NYSE:NVO) delivered promising data over the weekend for its next-generation weight-loss injection, CagriSema, showing it can achieve weight reductions on par with the most effective treatments currently available. Yet the subdued market reaction on Monday suggests growing investor unease about how the Danish drugmaker will hold its lead in a rapidly crowding space.
Novo Nordisk And Its Real Value
Novo Nordisk remains fundamentally strong with robust earnings growth, high ROE, ROIC, and gross margins, despite recent CEO change and short-term market concerns. The stock appears undervalued, trading below estimated fair value, and offers a potential 12-14% annual return for long-term investors. Key risks include US drug price negotiations, especially for Ozempic and Wegovy, which could impact revenue and create short-term volatility.
